Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.4M Sell
318,745
-20,539
-6% -$3.78M 0.11% 208
2025
Q4
$59.7M Sell
339,284
-578,741
-63% -$94.6M 0.1% 208
2025
Q3
$129M Buy
918,025
+124,743
+16% +$16.9M 0.22% 102
2025
Q2
$99.6M Buy
793,282
+27,961
+4% +$3.48M 0.19% 117
2025
Q1
$105M Buy
765,321
+78,771
+11% +$11.3M 0.27% 75
2024
Q4
$105M Sell
686,550
-170,285
-20% -$28.7M 0.28% 71
2024
Q3
$166M Buy
856,835
+799,240
+1,388% +$167M 0.43% 30
2024
Q2
$13.4M Buy
57,595
+954
+2% +$207K 0.03% 586
2024
Q1
$12.2M Sell
56,641
-13,367
-19% -$3.13M 0.03% 616
2023
Q4
$18.1M Buy
+70,008
New +$17.2M 0.05% 435
2023
Q3
Sell
-170,811
Closed -$45.7M 276
2023
Q2
$48.7M Buy
+170,811
New +$50.8M 0.15% 149
2023
Q1
Sell
-695,284
Closed -$192M 89
2022
Q4
$193M Buy
695,284
+26,106
+4% +$7.37M 0.69% 14
2022
Q3
$179M Buy
+669,178
New +$142M 0.83% 10
2022
Q2
Sell
-820,811
Closed -$168M 14
2022
Q1
$173M Buy
820,811
+607,363
+285% +$132M 0.6% 17
2021
Q4
$51.2M Buy
213,448
+37,009
+21% +$9.52M 0.16% 125
2021
Q3
$49.9M Buy
176,439
+140,104
+386% +$45.9M 0.18% 127
2021
Q2
$12.6M Buy
36,335
+10,492
+41% +$3.18M 0.04% 479
2021
Q1
$7.23M Sell
25,843
-102,645
-80% -$27.7M 0.03% 546
2020
Q4
$31.5M Sell
128,488
-213,438
-62% -$55.1M 0.14% 146
2020
Q3
$97M Sell
341,926
-150,644
-31% -$42M 0.38% 45
2020
Q2
$132M Sell
492,570
-75,322
-13% -$22.6M 0.66% 26
2020
Q1
$180M Sell
567,892
-141,524
-20% -$42.9M 1.16% 9
2019
Q4
$211M Buy
709,416
+14,574
+2% +$4.04M 0.69% 13
2019
Q3
$162M Buy
694,842
+222,250
+47% +$51.8M 0.6% 24
2019
Q2
$111M Buy
472,592
+161,432
+52% +$37.3M 0.4% 35
2019
Q1
$73.6M Sell
311,160
-114,893
-27% -$36.2M 0.28% 65
2018
Q4
$128M Buy
426,053
+73,861
+21% +$23.6M 0.57% 32
2018
Q3
$124M Sell
352,192
-322
-0.1% -$111K 0.45% 32
2018
Q2
$102M Buy
352,514
+74,385
+27% +$20.9M 0.42% 34
2018
Q1
$76.2M Buy
+278,129
New +$86.3M 0.35% 47

Other funds holding BIIB

Man Group's BIIB Position: Q1 2026 in Review

Man Group reduced its Biogen (BIIB) stake by 6.1% in Q1 2026, selling an estimated $3.78M and leaving 318,745 shares worth $58.4M. The position accounts for 0.11% of the portfolio, ranked #208.

Man Group first reported a position in BIIB in Q1 2018 and has held it in 30 quarters since. The position peaked at $211M in Q4 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Man Group held 318,745 shares of Biogen worth $58.4M as of Q1 2026.
  • Man Group sold 20,539 Biogen shares in Q1 2026, an estimated $3.78M.
  • Biogen made up 0.11% of Man Group's portfolio in Q1 2026, its #208 holding.
  • Man Group first reported a position in Biogen in Q1 2018 and has held it in 30 quarters since.
  • Man Group's Biogen position peaked at $211M in Q4 2019.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.